Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.765
+0.035 (0.94%)
Aug 10, 2026, 10:06 AM EDT - Market open
Pyxis Oncology Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Pyxis Oncology stock has a consensus rating of "Strong Buy" and an average price target of $7.33. The average 1-year stock price forecast is 94.69% higher than the current stock price, while the lowest is $5.00 (+32.80%) and the highest is $12 (+218.73%).
Price Target: $7.33 (+94.69%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Pyxis Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 8 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Initiates $12 | Buy | Initiates | $12 | +218.73% | Aug 3, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $5 | Buy | Maintains | $5 | +32.80% | Jul 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 | Buy | Reiterates | $7 | +85.92% | Jul 6, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $8 | Buy | Maintains | $8 | +112.48% | Jul 3, 2026 |
| William Blair | William Blair | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 30, 2026 |
Financial Forecast
Revenue This Year
44.44K
from 13.86M
Decreased by -99.68%
Revenue Next Year
2.78M
from 44.44K
Increased by 6,150.63%
EPS This Year
-1.22
from -1.28
EPS Next Year
-1.20
from -1.22
EPS and Forward PE are based on non-GAAP adjusted numbers.